{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:08:53Z","timestamp":1793657333219,"version":"4.5.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T00:00:00Z","timestamp":1571443200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T00:00:00Z","timestamp":1571443200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and\/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and\/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3\u00a0months and at 1\u00a0year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty-three patients with median age of 73\u00a0years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was<jats:italic>Staphylococcus aureus<\/jats:italic>in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12\u00a0months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3\u00a0months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636\u00a0days for BSI (315,424.20\u20ac) and 557\u00a0days for IE (283,187.45\u20ac).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and\/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic\/pharmacodynamic profile of this drug.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12941-019-0329-6","type":"journal-article","created":{"date-parts":[[2019,10,19]],"date-time":"2019-10-19T14:02:22Z","timestamp":1571493742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6394-5728","authenticated-orcid":false,"given":"Carmen","family":"Hidalgo-Tenorio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vinuesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Plata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Martin D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Iftimie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Sequera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"Loeches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Eduardo","family":"Lopez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari Carmen","family":"Fari\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Fern\u00e1ndez-Roldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Javier-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Mar","family":"Arenas-Miras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"Mart\u00ednez-Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Maria","family":"Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Bereciartua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha E.","family":"De Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Pasquau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,19]]},"reference":[{"key":"329_CR1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ehjqcco\/qcw039","volume":"3","author":"FS Van den Brink","year":"2017","unstructured":"Van den Brink FS, Swaans MJ, Hoogendijk MG, Alipour A, Kelder JC, Jaarsma W. European Society of Cardiology guideline update: a nationwide study in the Netherlands. Eur Heart J Qual Care Clin Outcomes. 2017;3:141\u20137.","journal-title":"Eur Heart J Qual Care Clin Outcomes."},{"key":"329_CR2","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jacc.2016.10.066","volume":"69","author":"TJ Cahill","year":"2017","unstructured":"Cahill TJ, Baddour LM, Habib G, Salaun E, Pettersson GB, et al. Challenges in infective endocarditis. J Am Coll Cardiol. 2017;69:325\u201344.","journal-title":"J Am Coll Cardiol."},{"key":"329_CR3","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","volume":"36","author":"G Habib","year":"2015","unstructured":"Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36:3075\u2013128.","journal-title":"Eur Heart J."},{"key":"329_CR4","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa1808312","volume":"380","author":"K Iversen","year":"2019","unstructured":"Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380:415\u201324.","journal-title":"N Engl J Med."},{"key":"329_CR5","first-page":"115","volume":"32","author":"C Ferrer","year":"2014","unstructured":"Ferrer C, Almirante B. Infecciones relacionadas con el uso de cat\u00e9teres vasculares. EIMC. 2014;32:115\u201324.","journal-title":"EIMC."},{"key":"329_CR6","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1128\/AAC.01021-12","volume":"57","author":"YP Chong","year":"2013","unstructured":"Chong YP, Moon SM, Bang KM, Park HJ, Park SY, Kim MN, et al. Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse: analysis of a prospective observational cohort study. Antimicrob Agents Chemother. 2013;57:1150\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"329_CR7","doi-asserted-by":"publisher","first-page":"E270","DOI":"10.3390\/microorganisms7080270","volume":"7","author":"D Koulenti","year":"2019","unstructured":"Koulenti D, Xu E, Mok IYS, Song A, Karageorgopoulos DE, Armaganidis A, Lipman J, Tsiodras S. Novel antibiotics for multidrug-resistant gram-positive microorganisms. Microorganisms. 2019;7:E270.","journal-title":"Microorganisms."},{"key":"329_CR8","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1086\/427283","volume":"40","author":"I Raad","year":"2005","unstructured":"Raad I, Darouiche R, Vazquez J, Lentnek A, Hachem R, Hanna H, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positve pathogens. Clin Infect Dis. 2005;40:374\u201380.","journal-title":"Clin Infect Dis."},{"key":"329_CR9","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.ijantimicag.2017.11.008","volume":"51","author":"E Bouza","year":"2018","unstructured":"Bouza E, Valerio M, Soriano A, Morata L, Carus EG, Rodr\u00edguez-Gonz\u00e1lez C, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018;51:571\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"329_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","volume":"67","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, et al. Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna). Clin Infect Dis. 2018;67:795\u20138.","journal-title":"Clin Infect Dis"},{"key":"329_CR11","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/S0213-005X(08)75281-9","volume":"26","author":"B Almirante","year":"2008","unstructured":"Almirante B, Mir\u00f3 JM. Infections associated with prosthetic heart valves, vascular prostheses, and cardiac pacemakers and defibrillators. Enferm Infecc Microbiol Clin. 2008;26:647\u201364.","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"329_CR12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1086\/381971","volume":"38","author":"R Ben-Ami","year":"2004","unstructured":"Ben-Ami R, Giladi M, Carmeli Y, Orni-Was-serlauf R, Siegman-Igra Y, et al. Hospital-acquired infective endocarditis: should the definition be broadened? Clin Infect Dis. 2004;38:843\u201350.","journal-title":"Clin Infect Dis"},{"key":"329_CR13","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0213-005X(07)74236-2","volume":"25","author":"JM Cisneros-Herreros","year":"2007","unstructured":"Cisneros-Herreros JM, Cobo-Reinoso J, Pujol-Rojo M, Rodr\u00edguez-Ba\u00f1o J, Salavert-Llet\u00ed M. Guidelines for the diagnosis and treatment of patients with bacteriemia. Guidelines of the Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Enfer Infecc Microbiol Clin. 2007;25:75\u2013164.","journal-title":"Enfer Infecc Microbiol Clin"},{"key":"329_CR14","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.jclinepi.2008.01.006","volume":"61","author":"ME Charlson","year":"2008","unstructured":"Charlson ME, Charlson RE, Paterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61:1234\u201340.","journal-title":"J Clin Epidemiol"},{"key":"329_CR15","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1136\/bmj.39503.424653.80","volume":"336","author":"JC Milton","year":"2008","unstructured":"Milton JC, Hill-Smith I, Jackson SH. Prescribing for older people. BMJ. 2008;336:606\u20139.","journal-title":"BMJ"},{"key":"329_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S0140-6736(07)61092-7","volume":"370","author":"A Mallet","year":"2007","unstructured":"Mallet A, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370:185\u201391.","journal-title":"Lancet."},{"key":"329_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/23744235.2017.1296968","volume":"49","author":"RP Dash","year":"2017","unstructured":"Dash RP, Babu RJ, Srinivas NR. Review of the pharmacokinetics of dalbavancin, a recently approved lipoglycopeptide antibiotic. Infect Dis. 2017;49:483\u201392.","journal-title":"Infect Dis"},{"key":"329_CR18","first-page":"B5128","volume":"62","author":"SL Nilesen","year":"2015","unstructured":"Nilesen SL. The incidence and prognosis of patients with\u00a0bacteremia. Dan Med. J. 2015;62:B5128.","journal-title":"Dan Med. J"},{"key":"329_CR19","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1136\/jim-2015-000040","volume":"64","author":"H Alkhawam","year":"2016","unstructured":"Alkhawam H, Sogomonian R, Zaiem F, Vyas N, El-Hunjul M, Jolly J, et al. Morbidity and mortality of infective endocarditis in a hospital system in New York City serving a diverse urban population. J Investig Med. 2016;64:1118\u201323.","journal-title":"J Investig Med."},{"key":"329_CR20","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.diagmicrobio.2016.05.009","volume":"85","author":"J Fern\u00e1ndez","year":"2016","unstructured":"Fern\u00e1ndez J, Greenwood-Quaintance KE, Patel R. In vitro activity of dalbavancin against biofilms of staphylococci isolated from prosthetic joint infections. Diagn Microbiol Infect Dis. 2016;85:449\u201351.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"329_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.diagmicrobio.2017.09.015","volume":"90","author":"K Neudorfer","year":"2018","unstructured":"Neudorfer K, Schmidt-Malan SM, Patel R. Dalbavancin is active\u00a0in vitro against biofilms formed by dalbavancin-susceptible enterococci. Diagn Microbiol Infect Dis. 2018;90:58\u201363.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"329_CR22","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1099\/jmm.0.000749","volume":"67","author":"C D\u00edaz-Ru\u00edz","year":"2018","unstructured":"D\u00edaz-Ru\u00edz C, Alonso B, Cercenado E, Cruces R, Bouza E, Mu\u00f1oz P, Guembe M. Can dalbavancin be used as a catheter lock solution? J Med Microbiol. 2018;67:936\u201344.","journal-title":"J Med Microbiol."},{"key":"329_CR23","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169\u201379.","journal-title":"N Engl J Med"},{"key":"329_CR24","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1086\/497271","volume":"41","author":"LE Jauregui","year":"2005","unstructured":"Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, et al. Randomized, double-blind comparison of once-weekly\u00a0dalbavancin\u00a0versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005;41:1407\u201315.","journal-title":"Clin Infect Dis"},{"key":"329_CR25","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/jac\/dkl281","volume":"58","author":"CE Nord","year":"2006","unstructured":"Nord CE, Rasmanis G, Wahlund E. Effect of dalbavancin on the normal intestinal microflora. J Antimicrob Chemother. 2006;58:627\u201331.","journal-title":"J Antimicrob Chemother"},{"key":"329_CR26","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1001\/jama.2018.7596","volume":"320","author":"A Wang","year":"2018","unstructured":"Wang A, Gaca JG, Chu VH. Management considerations in infective endocarditis: a review. JAMA. 2018;320:72\u201383.","journal-title":"JAMA"},{"key":"329_CR27","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1093\/jac\/dkz162","volume":"74","author":"T Morrisette","year":"2019","unstructured":"Morrisette T, Miller MA, Montague BT, Barber GR, Mc Queen RB, Krask M. On- and off-label utilization of dalbavancin and oritavancin for Gram-positive infections. J Antimicrob Chemother. 2019;74:2405\u201316.","journal-title":"J Antimicrob Chemother"},{"key":"329_CR28","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cmi.2017.08.028","volume":"24","author":"R Agarwal","year":"2018","unstructured":"Agarwal R, Bartsch SM, Kelly BJ, Prewitt M, Liu Y, Chen Y, Umscheid CA. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. 2018;24:361\u20138.","journal-title":"Clin Microbiol Infect"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-019-0329-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12941-019-0329-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-019-0329-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T05:05:56Z","timestamp":1664687156000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-019-0329-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,19]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["329"],"URL":"https:\/\/doi.org\/10.1186\/s12941-019-0329-6","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,19]]},"assertion":[{"value":"15 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethical committee of the coordinating centre. All patients had given consent to the use of their data for research purposes. All data were gathered in accordance with Spanish personal data protection legislation (law of 15\/1999, 13 December).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors contributed significantly to the work presented and the preparation of the manuscript, and all read and approved the final submitted version.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}